Real-World Studies
Complex Karyotype and Non-BTK Mutations Linked to BTK Inhibitor Resistance in CLL
Mashima et alBritish journal of haematology

A retrospective analysis evaluated 646 patients with chronic lymphocytic leukaemia (CLL) treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana-Farber Cancer Institute between 2014 and 2023. Among this cohort, 122 patients underwent next-generation sequencing (NGS) during or at the next visit following BTKi therapy, which included ibrutinib (n = 85), acalabrutinib (n = 23), pirtobrutinib (n = 9), zanubrutinib (n = 4), and vecabrutinib (n = 1).
Patients sequenced at disease progression (PD group, n = 47) exhibited higher rates of 17p deletion, complex karyotype, heavier prior treatment exposure, and prior exposure to an alternate BTKi relative to non-progressors (NP group, n = 75). Genomic profiling identified 321 mutations across 67 genes, with a higher burden observed in the PD group (231 mutations), including 39 BTK mutations (C481S/F/R/Y, L528W, and T474I/L) and 26 phospholipase C gamma 2 (PLCG2) mutations. In 12 PD patients with serial samples available, all acquired new or expanded BTK or TP53 mutations.
Complex karyotype, specifically 8p loss, was significantly enriched in the PD cohort. Furthermore, mutations in tumour protein p53 (TP53), splicing factor 3b subunit 1 (SF3B1), protein phosphatase, Mg2+/Mn2+ dependent 1D (PPM1D), and notch receptor 2 (NOTCH2) were significantly more prevalent in the PD group (all p < 0.05). Pathogenic mitogen-activated protein kinase (MAPK) pathway mutations also trended toward higher frequency and exhibited higher variant allele frequencies in progressive patients (p = 0.047), suggesting that TP53 aberrations, 8p-loss-associated complex karyotype, and specific non-BTK driver mutations are enriched in BTKi resistance.
Key Takeaways
- Complex karyotype—specifically 8p loss—and mutations in TP53, SF3B1, PPM1D, and NOTCH2 were significantly more prevalent in patients progressing on BTK inhibitors compared with non-progressors (all p < 0.05).
- Pathogenic mitogen-activated protein kinase (MAPK) pathway mutations trended more common and exhibited higher variant allele frequencies in the progressive disease cohort (p = 0.047).
Read the original sourceBritish journal of haematology
